ALNY FY 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.2B+23.0% YoY

Gross Profit

$1.9B85.6% margin

Operating Income

-$177M-7.9% margin

Net Income

-$278M-12.4% margin

EPS (Diluted)

$-2.18

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$43M

Stock-Based Comp.

$272M

Balance Sheet

Total Assets

$4.2B

Total Liabilities

$4.2B

Stockholders' Equity

$67M

Cash & Equivalents

$966M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$1.8B	+23.0%
Gross Profit	$1.9B	$1.5B	+26.8%
Operating Income	-$177M	-$282M	+37.3%
Net Income	-$278M	-$440M	+36.8%